Qiagen artus CMV RGQ MDx Kit

Thursday, 19 June, 2014 | Supplied by: QIAGEN Pty Ltd



Qiagen’s artus CMV RGQ MDx Kit for human cytomegalovirus (CMV) has been approved by the US Food and Drug Administration (FDA) under a full premarket approval (PMA). The PCR-based assay is optimised for low- to mid-throughput testing of CMV.

CMV testing is primarily used as an aid in the management of solid organ transplant patients to assess viral load in response to antiviral drug therapy. These patients are at high risk of life-threatening CMV infections in the months following surgery, and antiviral drug treatment is standard. Between 20 and 60% of all transplant patients, depending on patient and procedure, are repeatedly tested for CMV throughout the first year following transplantation.

Qiagen’s CMV assay is claimed to be the fastest test approved for quantifying CMV viral loads in organ transplant patients. In addition to helping save lives, the test reduces the time and money labs and hospitals currently spend validating lab-developed CMV tests and analyte-specific reagents. The assay has a turnaround time of approximately 3 h and runs on Qiagen’s Rotor-Gene Q MDx real-time PCR platform, a member of the QIAsymphony modular family of automated instruments.

Online: www.qiagen.com
Phone: 03 9840 9800
Related Products

Bruker B.I.QUANT-UR 1.1 module for metabolite quantification in urine

Bruker's B.I.QUANT-UR 1.1 module automatically quantifies up to 150 endogenous and...

Thermo Fisher Scientific Ion Torrent CarrierSeq ECS Kit

The Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 System consolidates a multiplatform...

BTX ECM 2001+ Electrofusion and Electroporation System

The BTX ECM 2001+ Electrofusion and Electroporation System is suitable for improving hybridoma...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd